Connect with us

Featured

Uber Technologies (UBER) Stock Corrects After Earnings, Good Time To Buy Tech Stocks?

Joe Samuel

Published

on

Uber stock price

Taxi-hailing company Uber Technologies Inc. (NYSE:UBER) stock price plunged to its lowest since the company went public. The stock is currently trading at $37.00 which is below the IPO price of $45. This is not the first time UBER stock is closing on a low having dropped to $37.01 on May 13.

This came after then CEO sent an email to staff indicating that the company’s long-term value will be realized eventually. The bleeding of the stock is currently being attributed to concerns about the company’s path to profitability. Unfortunately, it did little to address this in the second quarter.

Currently, there is a lot of pressure on CEO Dara Khosrowshahi. The company fell short of analyst’s bottom and top-line estimates after posting a huge loss of $5 billion. Uber also scored misses in gross bookings as well as adjusted revenue. Sales for UberEats and ride-sharing declined in the second quarter compared to a year ago.

Profitability concerns

The CEO’s frivolous attitude regarding Uber’s need to get into profitability going forward is even more worrying. In an earnings call, the Dara dismissively told an analyst on the issue of profitability that he was aware of a meme that has been around regarding whether the company will ever be profitable.

Wedbush analyst Dan Ives indicates that kit is difficult to believe the Uber story as it lacks Wall Street credibility. He has pointed to another near term concern for the company which is the expected expiration of its IPO lockup period that is coming on November 3.

On Friday Yahoo reported that the company had instituted a hiring freeze after the company informed job applicant to call off coming interviews. Uber confirmed that it had paused the hiring for product manager and engineering jobs except for positions in autonomous driving or freight.

Continue Reading
Click to comment

Featured

Stock Price Newsletter – November 12, 2019

Jon Phillip

Published

on

list of healthcare stocks to watch

Biotech Stocks To Watch This Week

Biotech penny stocks have proven to be one of the best sectors for investments. That’s as far as the stock market is concerned. If experts are to be believed then it may continue to be among the best options in the years to come…

Continue Reading


Streaming Stocks Take Aim At Winning The Content War

It has been projected that the industry is going to be worth $124.57 billion by 2025. That being said, there may be ample opportunity for investors. Here is a look at a few tech stocks to watch that could be set to prove themselves on this new battlefield.

See For Yourself


What Does The Disney (DIS) Plus, Amazon Deal Mean For Investors?

There is no doubt that 2019 and the years beyond are going to be definite by the ‘streaming wars’ between some of the biggest companies in the world. The imminent entry of a behemoth like Disney (DIS) has raised the stakes even higher and on Thursday the entertainment company made another significant announcement.

Click To Read More

Continue Reading

Featured

What Does The Disney (DIS) Plus, Amazon Deal Mean For Investors?

Jon Phillip

Published

on

DIS stocks to buy Disney +

There is no doubt that 2019 and the years beyond are going to be definite by the ‘streaming wars’ between some of the biggest companies in the world. The imminent entry of a behemoth like Disney (DIS) has raised the stakes even higher and on Thursday the entertainment company made another significant announcement.

During the company’s conference call for the fourth-quarter earnings, the Chief Executive Officer of Disney Bob Iger stated that the streaming serving Disney+ is going to be available on Amazon Fire TV.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

Major Development For Content Providers

This is a major development, considering the fact that Disney had earlier said that the service might not be available on products owned by Amazon due to advertising disagreements.

However, that is not all. Iger went on to state that the service will also be made available on Smart TV manufactures by LG and Samsung. During the conference call, the Disney CEO said, “We’re pleased to announce partnerships with Amazon Fire [TV], LG, and Samsung devices.”

It is a major development for a streaming service that is trying to capture market share quickly from Netflix. Availability on Amazon Fire makes it accessible to a far bigger pool of potential customers. That is why this particular announcement is so important.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

Where Does This Leave Netflix?

There are certain added benefits of the availability of Amazon Fire TV. The Disney+ app has the ability to sync with the built-in search engine on Amazon. Therefore, users will be able to request particular content by stating it to the personal assistant Alexa.

It goes without saying that the development has come as a big boost for Disney+. It’s ahead of the much-anticipated launch on November 12. The price of the service sits cheaper than Netflix’s cheapest package. It’s also going to be a highly cut-throat battle between the two companies. That said, other services are also coming soo. The ‘streaming wars’ are going to be the theme of 2020.

[MARKET PREVIEW] The $40 Billion Dollar Content Gold Rush

Continue Reading

Biotechnology

Biotech Stocks To Watch This Week

A. Lawrence

Published

on

make money with penny stocks biotech

With Biotech Continuing Higher, Are These Buys Or Sells This Week?

Biotech penny stocks have proven to be one of the best sectors for investments. That’s as far as the stock market is concerned. If experts are to be believed then it may continue to be among the best options in the years to come. That being said, it does not mean that investing in biotech stocks is an easy ride.

An investor needs to conduct a lot of research and also watch the market closely. Similar to other high-risk industries, volatility is a big factor. At any given point in time, a bad report could send stocks plummeting. Similarly, one good DA report can trigger a monster move. Here is a quick look at a few biotech penny stocks which made moves recently. Will they be better stocks to buy or avoid this month?

GT Biopharma Inc. (GTBP)

This company’s stock made new 3 month highs on October 22. GT Biopharma (GTBP) announced that its solid tumor targeting TriKE killed a non-small cell lung cancer tumor cell. This is a major development news for the company’s TriKE platform because the market potential for non-small lung cancer is big.

biotech stock to watch 2019

Non-small lung cancer accounts for 84% of all lung cancer diagnoses. Shareholders clearly felt this way, which may have been why GT Biopharma’s stock shot up by more than 25%.

There could be another potential reason why stockholders are reacting this way to the recent news. Earlier in October, the company announced that the design of HIV-TriKE was able to successfully target the HIV-Env protein.

This would allow the company’s TriKE technology to eliminate replicating HIV infected cells. Because of the success of TriKE with lung cancer cells, investors might feel that the company will be able to successfully destroy HIV cells. For more on GT Biopharma’s novel treatment pipeline and progress, click here.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, ITS INVESTORS & THE WORLD!

Pieris Pharmaceuticals (PIRS)

The first stock to consider in the biotech sector with regards to the latest movements is that of Pieris Pharmaceuticals Inc (NASDAQ:PIRS). Back on November 5, the company announced that dose escalation monotherapy data with regards to one of its products is going to be presented at the Immunotherapy of Cancer (SITC) Annual Meeting that is going to be held at National Harbor, Maryland.

stock_price_mental

The medicine in question is PRS-343, which is meant for treating HER2-positive solid tumors. It goes without saying that it is a positive development and the Pieris stock has reacted positively to the news as well. Since the news broke, the stock has gained as much as 10%.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, ITS INVESTORS & THE WORLD!

Foamix Pharmaceuticals (FOMX)

The other biotech stock that has been on a tear for much of the week is the Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) stock. Back on October 18, the company announced that one of its products known as AMZEEQ has been approved by the United States Food and Drug Administration. The medicine in question is a topical foam and is meant for treating inflammatory lesions in both adults as well as pediatric patients, who are older than 9. That was the initial trigger for the rise in the stock price.

Last week, the company also published a peer review of the long term open-label safety of AMZEEQ and that proved to be the trigger for the rally. During the course of the week so far, the Foamix stock has soared by as much as 60%. This is a stock that should definitely be tracked by investors.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, ITS INVESTORS & THE WORLD!

biotechnology stocks to buy

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com